Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Roberta Gagliardini
Institution:
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Observed institution:
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
ORCID:
0000-0002-6351-2623
Observed ORCID:
0000-0002-6351-2623
OpenAlex ID:
A5079758640
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
2025
·
Roberta Gagliardini
, Sara De Benedittis
, et al.
·
Journal of Antimicrobial Chemotherapy
·
22
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry
2024
·
Daniele Armenia
, Vincenzo Spagnuolo
, et al.
·
Journal of Antimicrobial Chemotherapy
·
7
Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)
2022
·
Ilaria Mastrorosa
, Roberta Gagliardini
, et al.
·
EClinicalMedicine
·
6
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
2025
·
Tommaso Clemente
, Golnaz Torkjazi
, et al.
·
Journal of Antimicrobial Chemotherapy
·
4
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation
2025
·
Cristina Mussini
, Andrea Giacomelli
, et al.
·
EClinicalMedicine
·
4
PDF
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulation
2025
·
Roberta Gagliardini
, Andrea Giacomelli
, et al.
·
International Journal of Infectious Diseases
·
3
PDF
Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry
2025
·
Vincenzo Spagnuolo
, Laura Galli
, et al.
·
Microbiology Spectrum
·
2
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)
2025
·
Roberta Gagliardini
, Marta Camici
, et al.
·
International Journal of Infectious Diseases
·
2
PDF
Telemedicine During COVID-19 Pandemic: Lesson Learned from the Lazio Region Infectious Diseases and Emergency Department Network
2022
·
Gaetano Maffongelli
, Nazario Bevilacqua
, et al.
·
Journal of Medical Systems
·
2
PDF
Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort
2026
·
Alessandra Vergori
, Adriana Cervo
, et al.
·
Open Forum Infectious Diseases
Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500 000 copies/mL in 2018–2023 in Italy: data from the ICONA Foundation Cohort Study
2026
·
Antonella d'Arminio Monforte
, Nicolò Lentini
, et al.
·
Clinical Microbiology and Infection
Determinants of non-compliance with additional booster doses of the SARS-CoV-2 vaccine in people living with HIV (PWH): An observational study based on a behavioral and epidemiological survey in Rome (Italy)
2025
·
Giulia Del Duca
, Isabella Sperduti
, et al.
·
Human Vaccines & Immunotherapeutics
PDF
All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry
2025
·
Andrea Giacomelli
, Nicolò Capra
, et al.
·
Clinical Infectious Diseases
PDF
Show more works
View as search
Works count:
17
Citation count:
65
H-index:
5
I10-index:
1
Year
Topic
Type